Solid-Phase Synthesis and *In Vitro* Cytotoxicity of New Peptide Functionalized Cyclencarboxymethylen and L-DOPA Hybrids

L Arabuli1,2*, R Jezek1, T Macek1, P Lovecka1, E Nikoleishvili1, N Sulashvili1 and I Maisuradze1

1Department of Pharmacy, University of Georgia, M. Kostava str. 77a, 0171 Tbilisi, Georgia
2Institute of Inorganic-organic Hybrid Compounds and Non-traditional Materials, Iv. Javakhishvili Tbilisi State University, Chavchavadze ave. 3, 0179 Tbilisi, Georgia
3Department of Biochemistry and Microbiology, University of Chemistry and Technology, Technická 5, 166 28 Praha 6-Dejvice, Czech Republic

Abstract

The new small peptide functionalized cyclen and DOPA derivatives were synthesized: cyclen-His-His, cyclen-AspHis, cyclen-GluHis, DOPA-HisHis were prepared. The solid-phase synthesis strategy was used for preparation of new compounds. Synthesized cyclen- and DOPA-oligopeptide hybrid conjugations were purified by HPLC and analyzed using MALDI-TOF MS spectrometer. The toxic effect was determined against mammalian cells human embryonic kidney cell line HEK293T ATCC®CL-11268TM for each new compound. The inhibition effect of all tested cyclen-oligopeptides on kidney cells was approximately about 30% after 24 hours. The minimal rate of toxicity against human liver cells showed all tested oligopeptides with DOPA, their inhibition effect was maximal 10%. The acute inhibition effect of sample DOPA-Glu-His-DOPA was 14% immediately after adding. The antioxidant and anticancer activity studies will be next part of the ongoing project.

Keywords: Cyclen; L-DOPA; Peptides; Solid-phase synthesis; *In vitro* cytotoxicity

Introduction

Macrocyclic polyamines are widely used in biology and medicine. The new methodologies for their selective functionalization are demanding due to their importance for a variety of diagnostic and therapeutic pharmaceuticals [1,2] and in the development of new MRI (Magnetic Resonance Imaging) contrast agents [3,4]. Recently, cyclen-based bifunctional chelators have attracted much interest in cancer therapy [5]. On the other hand, L-DOPA (3,4-dihydroxyphenylalanine) derivatives play a crucial role in the therapy of Parkinson disease (PD) as they increase the BBB penetration capacity of DOPA, which is well known medicine in the treatment of PD since 1960s. The DOPA peptidomimetics with amino acid cross-linked via oxygen atom were prepared and their antioxidant activities were studied [6].

In order to mimic biochemical processes, a number of receptor molecules have been synthesized for many biologically vital molecules and enzymes. It is well known, that in such receptors, hydrogen bonding, hydrophobic or electrostatic interactions play significant role, as complementary features of the host-guest molecules. The Zinc- macrocyclic polyamine mode complexes with [12]aneN3 (cyclam) and [12]aneN4 (cyclen) showed the strong nucleophile Zn2−-OH forms at physiological pH from Zn2−-H2O species [7] and logg value (6.4) indicates that OH group is weakly bound to the metal ion and thus, can attack to CO2 or carboxeites. By complexation of Zn2+ with [12]aneN3 (cyclam) and [12]aneN4 (cyclen) the pKa is lowering from 9.0 (Zn2+–H2O) to 7.3 and 7.9, respectively, at 25°C.

The modification of macrocyclic polyamine receptor molecules with additional ligands (arms) enables to interact with nucleobase, sugar and other biomolecules moieties for a more efficient “multipoint” recognition, as well as for thermodynamic stabilization of the ternary complexes in aqueous solution [8]. Cyclen derivatives showed antibacterial [9], anti-HIV and anti-malarial activities [10,11], zinc(II)-cyclen-peptide hybrid compounds as potential inhibitor for Ras-Ras interactions [12], as well as, macrocyclic polyamines, their derivatives, and metal complexes as potential therapeutic agents in Alzheimer’s disease treatment, were reported [13-16]. The most advantage of the macrocyclic polyamines is their unique capacity to bind some biologically important metals (Zn, Cu, Co, Fe) and their role was dramatically increased as behavior models for enzymes and other metalloproteins. On the other hand, it is important, to inhibit protein-protein interactions by small molecules, which are considered to be bi- or multivalent ligands leading to increase binding affinities providing additional binding sites [12]. In addition, Zn2+ and Cu2+ chelators are proposed as potential therapeutic agents for AD where redox reactions of metal-Aβ aggregates can be inhibited by chelators [17]. Recently, derivatives of 1,1′-xyllyl-bis-1,4,8,11-tetraazacyclododecane have been shown to be effective in reducing copper concentration and to maintain copper normal levels in rats [13]. On the other hand, macrocyclic polyamines such as cyclen and cyclam and their derivatives, as well as their metal complexes have wide applications in medicine [14,15]. It is important that toxicity of cyclen and cyclam is very low [18,19]. The detail investigation of these macrocyclic amines on the effect of metal-induced aggregation was carried out [20] and the chelators showed ability to increase solubility of large aggregates and prevented the formation of the β-sheet structure, as well as they inhibit hydrogen peroxide (H2O2) production by Cu-Aβ40 and therefore cyclen and cyclam as proposed as good candidates to cross blood-brain barrier and with low toxicity as potential neuroprotective or neurorescue agents in the treatment of Alzheimer’s disease.

Polyphenolic compounds, like coumarins and its derivatives are able to bind transition metal ions and inhibit hydroxyl radical and hydrogen peroxide formation produced by Fenton’s reactions [21] and by this way, potent reactive oxygen species (ROS) scavengers and metal chelators [21]. Polyphenol derivatives (or metabolites) found numerous therapeutic applications, such as central nervous system stimulants [22].

*Corresponding author: L Arabuli, Department of Pharmacy, University of Georgia, M. Kostava str. 77a, 0171 Tbilisi, Georgia; Tel: +995591048800, E-mail: l.arabuli@ug.edu.ge

Received December 18, 2017; Accepted December 20, 2017; Published December 27, 2017

Citation: Arabuli L, Jezek R, Macek T, Lovecka P, Nikoleishvili E, et al. (2017) Solid-Phase Synthesis and *In Vitro* Cytotoxicity of New Peptide Functionalized Cyclencarboxymethyl and L-DOPA Hybrids. Med Chem (Los Angeles) 7: 398-405. doi: 10.4172/2161-0444.1000487

Copyright: © 2017 Arabuli L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
antitumor and anti-HIV therapy [23], antibacterial [24], anticoagulants [25] etc. By phenolic compound, such as 6,7-hydroxycoumarin, with two hydroxyl moieties prevent formation and scavenging of ROS and influence radical-mediated oxidative damage, are considered as one of the most effective antioxidant compounds and used as an protectors against DNA damage, cancer and aging [26,27].

**Materials and Methods**

**General**

2-chlorotrityl chloride resin, N,N′-diisopropylcarbodiimide (DIC), piperidine (PIP) and Fmoc-protected amino acids: Fmoc-His(Trt)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH were purchased from Iris Biotech GmbH (Marktredwitz, DE); 1-hydroxybenzotriazole (HOBt), 1,4,7,10-tetraazacyclododecane (cyclen), 1,4,7-tri-Boc-10-(carboxymethyl)-tetraazacyclododecane (3N-Boc-cyclen), Aβ (1-16), and Fmoc-DOPA(acetonide)-OH were obtained from Bachem (Bubendorf, Switzerland). High performance liquid chromatography (HPLC) grade acetonitrile (ACN), isopropyl alcohol (IPA) and dimethylformamide (DMF) were from Lachner (Neratovice, CZE); All other chemicals were of analytical or reagent grade.

**Purification and identification**

After the synthesis, the crude products (dipeptides, cyclen-dipeptides, DOPA-dipeptides and cyclen-DOPA) were purified by RP-HPLC using a 100 min (3 ml/min) gradient from 0 to 100% ACN. For identification of synthesized compounds were analyzed by MALDI-TOFMS spectrometer.

**Experimental part**

**Solid-phase synthesis of cyclen/DOPA-peptides:** All peptide conjugations were synthesized manually by a stepwise strategy. The general procedure for each synthetic cycle, based on initial resin, was as follows:

1. attachment of Fmoc-His(Trt)-OH or Fmoc-DOPA(ac)-OH (Figure 1) on 2-chlorotrityl resin (S=1.55 mM/g), washings: DMF, i-ProH, DMF, each 3x1 min; (2) Deprotection-20% PIP in DMF for ~30 min; washings: DMF, i-ProH, DMF, each 3x1 min; (3) Coupling: HOBT 5 eq in DMF, coupling reagent (Fmoc-AA, 3N-Boc-Cyclen-CH₂COOH, Fmoc-DOPA(ac)-OH), 4 eq in DMF; 2M DIC/DMF, 7 eq; 20% PIP in DMF for 20-30 min; washings: DMF, i-PrOH, DMF, each 3x1 min; (4) Coupling: i-PrOH, DMF, each 3x1 min; (5) Cleavage of synthesized compounds from the resin and deprotection of side chains were performed in solution of 95% TFA, 2.5% TIS and 2.5% H₂O, the reaction time was 3.5 h followed by 3-4 TFA washing: TFA was removed with the stream of nitrogen. The products were precipitated with tert-ButOme and (Et)₂O ethers and collected by centrifugation (2000xg, 2 min).

**Cyclen-HisHis-Oh:** 3N-Boc-cyclen-55 mg (102 μM, 1.0 eq) in 200 μL, His(Trt)-His(Trt)-®-382 mg (204 μM, 1.0 eq), HOBT-29.0 mg (218 μM, 2.1 eq) in 50 μL DMF, BB-26 μL, DIC-153 μL (306 μM, 3.0 eq) in 50 μL DMF. Yield: crude-105.0 mg (87.2%), pure-54.1 mg (44.8%); MS (M + H)⁺ 501.

**Cyclen-AspHis-Oh:** 3N-Boc-cyclen-55 mg (102 μM, 1.0 eq) in 200 μL, Asp(O-tBu)-His(Trt)-®-277 mg (208 μM, 1.0 eq), HOBT-30.0 mg (218 μM, 2.1 eq) in 50 μL DMF, BB-27 μL, DIC-156 μL (312 μM, 3.0 eq) in 50 μL DMF. Yield: crude-88.0 mg (79.3%), pure-69.0 mg (62.2%); MS (M + H)⁺ 482.95.

**Cyclen-GluHis-Oh:** 3N-Boc-cyclen-55 mg (102 μM, 1.0 eq) in 200 μL, Glu(O-tBu)-His(Trt)-®-387 mg (204 μM, 1.0 eq), HOBT-29.0 mg (214 μM, 2.1 eq) in 50 μL DMF, BB-27 μL, DIC-153 μL (306 μM, 3.0 eq) in 50 μL DMF. Yield: crude-106.0 mg (87.4%), pure-59.4 mg (49.1%); MS (M + H)⁺ 471.49.

**DOPA-HisHis-Oh:** His(Trt)-His(Trt)-®-470 mg (250 μM, 1.0 eq), Fmoc-DOPA(ac)-OH-150 mg (326 μM, 1.3 eq) in 450 μL DMF, HOBT-51.0 mg (375 μM, 1.5 eq) in 300 μL DMF, BB-32 μL, DIC-288 μL (575 μM, 2.3 eq). Yield: crude-117.0 mg (86.5%), pure-76.0 mg (56.2%); MS (M + H)⁺ 471.49.

**DOPA-AspHis-Oh:** Asp(O-tBu)-His(Trt)-®-332 mg (250 μM, 1.0 eq), Fmoc-DOPA(ac)-OH-150 mg (326 μM, 1.3 eq) in 450 μL DMF, HOBT-51.0 mg (375 μM, 1.5 eq) in 250 μL DMF, BB-32 μL, DIC-288 μL (575 μM, 2.3 eq). Yield: crude-112.0 mg (84.1%), pure-80.6 mg (60.5%); MS (M + H)⁺ 497.

**DOPA-GluHis-Oh:** Glu(O-tBu)-His(Trt)-®-474 mg (250 μM, 1.0 eq), Fmoc-DOPA(ac)-OH-150 mg (326 μM, 1.3 eq) in 450 μL DMF, HOBT-51.0 mg (375 μM, 1.5 eq) in 250 μL DMF, BB-32 μL, DIC-288 μL (575 μM, 2.3 eq). Yield: crude-107.0 mg (79.2%), pure-60.8 mg (45.0%); MS (M + H)⁺ 463.49.

**Cyclen-DOPA:** 3N-Boc-cyclen-335 mg (631 μM, 1.1 eq) in 1.0 mL DMF, DOPA(ac)-®-800 mg (576 μM, 1.0 eq), HOBT-156.0 mg (1152 μM, 2.0 eq).

Figure 1: Substrates: 3N-cyclen-CH₂COOH and Fmoc-DOPA(ac)-OH.
µM, 2.1 eq) in 250 µL DMF, BB-74 µL, DIC-864 µL (1728 µM, 3.0 eq).
Yield: crude-291.0 mg (90.1%), pure-201.0 mg (62.2%); MS (M + H\(^+\)) 409.49.

**DOPA-HisHis-DOPA:** Fmoc-His(Trt)-OH-303 mg (490 µM, 2.0 eq) in 650 µL DMF, DOPA(ac)-\(^+\)-340 mg (245 µM, 1.0 eq), HOBt-83.0 mg (612.5 µM, 2.5 eq) in 120 µL DMF, BB-31 µL, DIC-429 µL (858 µM, 3.5 eq). Coupling with another His: Fmoc-His(Trt)-OH-380 mg (613 µM, 2.5 eq) in 800 µL DMF, HOBt-102.0 mg (760 µM, 3.1 eq) in 180 µL DMF, BB-31 µL, DIC-536 µL (1072 µM, 4.3 eq). Coupling with another DOPA: Fmoc-DOPA(ac)-OH-123 mg (270 µM, 1.1 eq) in 150 µL DMF, HOBt-66.0 mg (490 µM, 2.0 eq) in 300 µL DMF, BB-31 µL, DIC-370 µL (735 µM, 3.0 eq). Yield: crude-215.1 mg (80.3%), pure-190.2 mg (70.9%); MS (M + H\(^+\)) 650.38.

**DOPA-AspHis-DOPA:** Fmoc-His(Trt)-OH-303 mg (490 µM, 2.0 eq) in 650 µL DMF, DOPA(ac)-\(^+\)-340 mg (245 µM, 1.0 eq), HOBt-83.0 mg (612.5 µM, 2.5 eq) in 120 µL DMF, BB-31 µL, DIC-429 µL (858 µM, 3.5 eq). Coupling with Asp: Fmoc-Asp(O-bu)-OH-252 mg (613 µM, 2.5 eq) in 800 µL DMF, HOBt-102.0 mg (760 µM, 3.1 eq) in 180 µL DMF, BB-31 µL, DIC-536 µL (1072 µM, 4.3 eq). Coupling with another DOPA: Fmoc-DOPA(ac)-OH-123 mg (270 µM, 1.1 eq) in 150 µL DMF, HOBt-66.0 mg (490 µM, 2.0 eq) in 300 µL DMF, BB-31 µL, DIC-370 µL (735 µM, 3.0 eq). Yield: crude-247.0 mg (85.6%), pure-203.1 mg (70.4%); MS (M + H\(^+\)) 628.38.

**DOPA-GluHis-DOPA:** Fmoc-His(Trt)-OH-303 mg (490 µM, 2.0 eq) in 650 µL DMF, DOPA(ac)-\(^+\)-340 mg (245 µM, 1.0 eq), HOBt-83.0 mg (612.5 µM, 2.5 eq) in 120 µL DMF, BB-31 µL, DIC-429 µL (858 µM, 3.5 eq). Coupling with Glu: Fmoc-Glu(O-tBu)-OH-261 mg (613 µM, 2.5 eq) in 800 µL DMF, HOBt-102.0 mg (760 µM, 3.1 eq) in 180 µL DMF, BB-31 µL, DIC-536 µL (1072 µM, 4.3 eq). Coupling with another DOPA: Fmoc-DOPA(ac)-OH-123 mg (270 µM, 1.1 eq) in 150 µL DMF, HOBt-66.0 mg (490 µM, 2.0 eq) in 300 µL DMF, BB-31 µL, DIC-370 µL (735 µM, 3.0 eq). Yield: crude-188.2 mg (77.2%), pure-120.1 mg (41.9%); MS (M + H\(^+\)) 642.38.

**Cytotoxicity Assay**

Monitoring of cell growth with the RTCA DP instrument: Experiments were carried out using the xCELLigence RTCA DP instrument (Roche Diagnostics GmbH, Mannheim, Germany) which was placed into a incubator (37°C and 5% CO\(_2\)). Cell proliferation and cytotoxicity experiments were performed using modified 16-well plates (E-plate, Roche Diagnostics GmbH, Mannheim, Germany).

Microelectrodes were attached at the bottom of the wells for impedance-based detection of attachment, spreading and proliferation of the cells. Initially, 100 µL of cell-free growth medium (10% FBS, 1% MEM) was added to the wells.

Cells were incubated from exponential phase cultures by a standardized detachment procedure using 0.25% Trypsin-EDTA and counted automatically using Roche’s CASY Cell Counter and Analyzer. 100 µL of the cell suspension was seeded into the wells at 10\(^{4}\) HEK-293T cells/ml for cytotoxicity experiments. Twenty-four hours after cell seeding were added tested substances dissolved in water (concentration 50 µg/ml) and also during a period of 72 hours with water. Water was added to control wells. CI (cell index) was monitored every 60 min during the experiment for 72 hours. This results into growth curves (dependence of the impedance expressed by the 'cell index' value on time) of monitored cells in the presence of individual substances. HEK-293T ATCC CRL-11268\(^{8}\) are epithelial cells derived from kidney of human fetus. HEK-293T cells were cultivated in Dulbecco’s modified Eagle's medium (DMEM; with 4.5 g/L glucose and L-Glutamine), supplemented with 10% fetal bovine serum (FBS) and 1% of MEM (mix of vitamins-Gibco, GB. Cells were cultured at 37°C and 5% CO\(_2\). cultivation medium was changed every 2 to 3 days. For experimental procedures, cells were seeded in 96-well plates at a concentration of 10\(^{5}\) cells/ml per well.

**Results and Discussion**

The new small peptide functionalized cyclen and DOPA derivatives were synthesized: cyclen-HisHis, cyclen-AspHis, cyclen-GluHis, DOPA-HisHis, DOPA-AspHis, DOPA-GluHis, DOPA-HisHis-DOPA, DOPA-AspHis-DOPA, DOPA-GluHis-DOPA and DOPA-cyclen (Figure 2). The solid-phase synthesis strategy was used for preparation of new compounds. The His-rich cyclen conjugations could be served as DNA, ATP and other biomolecules recognition models, as bifunctional molecules (protein interaction and metal chelation) in metal chelation therapy approach and polyphenolic DOPA derivatives, as metal chelators and radical scavengers. The general synthetic procedure is given on Scheme 1 and 2. We prepared the cyclen carboxymethyl derivatives with tertBut and Trt-protected dipeptides, including HisHis, GluHis and AspHis, and Dopa-substituted carboxymethylcyclencencencyclen. Compound 1 (Fmoc-His(Trt)-OH, 4.61 g, 7.44 mM, 1.2 eq.) was dissolved in DMF and 4.21 mL (24.8 mM, 4.0 eq) disopropylethylamine (DIEA) was added to the syringe with 2-chlorotriethyl chloride resin (S=1.55 mg/g, 4.0 g, 6.2 mM, 1 eq), which was preliminarily washed with THF (3x) and swelled in DCM (CHCl\(_3\)). The syringe was shaken for ~5 hrs at room temperature. As color turned from yellow to brown-orange, the reaction content was washed with DMF, i-PROH, DMF (3x). The Fmoc-His(Trt)-\(^\ast\) was dried and half of this His-attached resin was swelled for 20 min, 20% Piperidine (PIP) in DMF was added for Fmoc-deprotection for 30 min. The another portion of Fmoc-His(Trt)-\(^\ast\) (2.73 g, 4.4 mM, 2 eq), HOBt (0.74 g, 5.5 mM, 2.5 eq), 2M DIC/DMF solution (3.85 mL, 7.7 mM, 3.5 eq) and 0.1% bromophenol blue (286 µL) were added. The reaction was shaken for overnight until color turned from bluin yellow. The Fmoc group was deprotected again 20% PIP, washed and dried. Finally, the crude H-(His(Trt)-\(^\ast\)) product was deprotected with 95% THF (2.5% TIS, 2.5% H\(_2\)O), then acids were removed under N\(_2\) stream and product was extracted with MeOH and Et\(_2\)O ethers. The crude products were purified by HPLC. Solvents were removed by rotovap and lyophilized to obtain colorless crystals.

N-functionalization of tetraazamacrocycles and their derivatives has been reported [28-30]. Generally, modification of such compounds is occurring via n-derivatization by a) derivatization and b) protection-derivatization-deprotection [28-30]. Synthesis of tetraazamacrocycle-KLVFF hybrids-the amide-or triazole linked derivatives and their metal complexes were reported [31] using Fmoc-strategy solid phase synthesis on Wang resin and subsequent coupling with tri-Boc-tetraazamacrocycle-acetic acid. These hybrid compounds showed neuroprotective effects of Ab in Alzheimer’s disease. The cyclen and cyclen were attached to the synthetic pentapeptide-KLVFF, a short Ab fragment (Ab16-20) which was chosen for amyloidal recognition and disruption of aggregates into fibrils [32, 33]. The glycine and triazole spacers were additionally incorporated in tetraazamacrocycles hybrids. On the other hand, dopaminergic precursors, such as levodopa (L-Dopa) or dopaminergic compounds are generally used for the treatment of Parkinson’s disease [34, 35]. Parkinson’s disease treatment efforts are concerned to the improvement of BBB permeability of candidate molecules, and thus, brain delivery [36, 37]. With this aim, L-dopa dipeptide derivatives using non-natural amino acids were prepared and...
their antiparkinsonian activity was studied [38] and amide derivatives of L-Dopa [39], from which the higher promising prodrug was diacetyl derivative of the simple L-Dopa amide.

The new compounds were derived with good yield. Possible cytotoxicity of new biological active peptides to mammalian cells is another disadvantage in their potential clinical use. Testing of the biological properties of peptides includes the determination of cytotoxic activity to the basic test parameters. To measure cytotoxicity, a system was used to assess the viability of adhering cells based on their degree of adhesion to the bottom of the microtiter plate, or a decrease in resistance between the surface of the electrodes and the culture medium. Next we investigated the toxic effect against mammalian cells human embryonic kidney cell line HEK293T ATCC®CLR-11268TM with each peptide. Toxic activity was determined in concentration 50 µg/ml. Figure 3 shows proliferation curves of cell line HEK 293T after adding group of cyclens of different dipeptides. The inhibition effect of

Figure 2: Structures of dipeptide derivatives of carboxymethylcyclo, DOPA and DOPA-cyclo hybrids.
Scheme 1: Stepwise reaction of functional derivation of tri-N-Boc-Cyclen-CH$_2$COOH with dipeptide (HH, DH, EH).

Scheme 2: Stepwise reaction of modification of Fmoc-DOPA(ac)-OH with dipeptides.
Cell line HEK 293T (concentration of cell $10^6$ cell/ml) Concentration of samples 50 µg/ml

Figure 3: Proliferation curves of cell line HEK 293T (concentration of cell $10^6$/ml) after adding tested samples (green-control, blue-cyclen-HisHis, pink-cyclen-GluHis, turquoise- cyclen-AspHis; red arrow-sample added.

Figure 4: Proliferation curves of cell line HEK 293T (concentration of cell $10^6$/ml) after adding tested samples (green-control, blue-DOPA-HisHis, pink-DOPA-GluHis, turquoise-DOPA-AspHis; red arrow-sample added.

all tested cyclen–dipeptides on kidney cells was approximately about 30% after 24 hours. The minimal rate of toxicity against human liver cells showed all tested dipeptides with DOPA, their inhibition effect was maximal 10% (Figure 4). The acute inhibition effect of sample DOPA-GluHis-DOPA was 14% immediately after adding (Figure 5).

The obtained results showed that further analyses and testing will be followed, such as anticancer and antioxidant activities, interaction with aggregated amyloid beta peptide and toxicity on neuronal cells will be observed in vitro.

Conclusion

The new small peptide functionalized cyclen and DOPA derivatives - cyclen-HisHis, cyclen-AspHis, cyclen-GluHis, cyclen-DOPA, DOPA-HisHis, DOPA-AspHis, DOPA-Glu-His, DOPA-HisHis-DOPA, DOPA-AspHis-DOPA and DOPA-Glu-His-DOPA were prepared. The solid-phase synthesis strategy was used for preparation of new compounds. Synthesized cyclen- and DOPA-oligopeptide hybrid conjugations were purified by RP-HPLC and analyzed using MALDI TOF MS spectrometer. The toxic effect was determined
against mammalian cells human embryonic kidney cell line HEK293T ATCC®CLR-11268™ for each new compound. Toxic activity was determined in concentration 50 µg/ml. The inhibition effect of all tested cyclen–dipeptides on kidney cells was approximately about 30% after 24 hours. The minimal rate of toxicity against human liver cells showed all tested dipeptides with DOPA, their inhibition effect was maximal 10%. The acute inhibition effect of sample DOPA-GluHis-DOPA was 14% immediately after adding. Their antioxidant and anticancer activities will be studied based on the obtained toxicity results.

Acknowledgement

The financial support from the Visegrad International Fund and an internal grant of the University of Georgia (school of health sciences and public health) are gratefully acknowledged.

References

1. Aoki S, Kimura E (2004) Zinc-nucleic acid interaction. Chem Rev 104: 769-788.
2. Bradshaw JS, Krakowiak KE, Izatt RM (1993) The chemistry of heterocyclic compounds, Wiley and Sons, Inc: 16-21, 83-85, 157-165.
3. Caravan PJ, Ellison J, McMurray TJ, Lauffer RB (1999) Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem Rev 99: 2293-2352.
4. Cakic N, Gunduz S, Rengarasu R, Angelovski G (2015) Synthetic strategies for preparation of cyclen-based MRI contrast agents. Tetrahedron Letters 56: 759-765.
5. Liu S, Edwards DS (2001) Bisfunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconj Chem 12: 7-34.
6. Mattia Bazzarri B, Pieri C, Botta G, Arabuli L, Mosesso P, et al. (2015) Synthesis and antioxidant activity of DOPA peptidomimetics by a novel IBX mediated aromatic oxidative functionalization. RSC Advances 5: 60354-60364.
7. Kimura E, Shioda T, Koike T, Shiota M, Kodama M (1990) A zinc(II) complex of 1,5,9-triazacyclododecane ([12]aneN3) as a model for carbonic anhydrase. J Am Chem Soc 112: 5805-5811.
8. Kimura E, Shionoya M (1994) Macrocyclic polyamine complex beyond metalloenzyme models. In: Transition metals in supramolecular chemistry. Kluwer Academic Publishers: 245-259.
9. Chen Q, Ma Z, Liu G, Wei H, Xie X (2016) Antibacterial activity of cationic cyclen-functionalized fullerene derivatives: membrane stress. Digest Journal of Nanomaterials and Biostructures 11: 753-761.
10. Khan MOF, Levi MS, Tekwani BL, Khan SJ, Kimura E, et al. (2009) Synthesis and Antimarial Activities of Cyclen 4-Aminoquinoline Analogs. Antimicrobial Agents and Chemotherapy 53: 1320-1324.
11. Amoyaw PN, Pham K, Cain AN, McClain JM, Hubin TJ, et al. (2014) Synthesis of Novel Tetraazamacrocyclic Bisquinoline Derivatives as Potential Antimalarial Agents. Current Org Synthesis 11: 916-921.
12. Schmidt F, Rosnizeck IC, Spoemer M, Kalbitzer HR, König B (2001) Zinc(II) cyclen-peptide conjugates interacting with the weak effector binding state of Ras. Inorg Chem Acta 365: 38-48.
13. Moret V, Laras Y, Pietrancosta N, Garino C, Quelever G, et al. (2006) 1, 1′-Xylyl bis-1, 4, 8, 11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer’s disease. Bioorg Med Chem Lett 16: 3298-3301.
14. Liang XY, Sadler PJ (2004) Cyclam complexes and their applications in medicine. Chem Soc Rev 33: 246-266.
15. Delgado R, Felix V, Lima LM, Price DW (2007) Metal complexes of cyclen and cyclam derivatives useful for medical applications: a discussion based on thermodynamic stability constants and structural data. Dalton Trans 26: 2734-2745.
16. Chen T, Wang X, He Y, Zhang Ch, Wu Z, et al. (2009) Effects of cyclen and cyclam on zinc(II)- and copper(II)-induced amyloid β-peptide aggregation and neurotoxicity. Inorg Chem 48: 5801-5809.
17. Daraeva C, Pitic M, Meunier B (2006) Influence of chelators and iron ions on the production and degradation of H2O2 by beta-amyloid-copper complexes. J Inorg Biochem 100: 2117-2126.
18. Pilchowski JF, Michelot J, Borel M, Meynigel G (1983) Enhanced elimination of 64Cu in rats by cyclen, a macrocyclic polynamine. Naturwissenschaften 70: 201-202.
19. Srivastava A, Katliyar SS, Behari JR, Hasan SK, Srivastava SK, et al. (1988) Evaluation of LD50 of some macrocyclic drugs and their linear analogues used as chelating drugs in metal intoxication. Chemosphere 17: 839-844.
20. Chen T, Wang X, He Y, Zhang Ch, Wu Z, et al. (2009) Effects of cyclen and cyclam on zinc(II)- and copper(II)-induced amyloid β-peptide aggregation and neurotoxicity. Inorg Chem 48: 5801-5809.
21. Marques ES, Salles DB, Maistro EL (2015) Assessment of the genotoxic/clastogenic potential of coumarin derivative 6,7-dihydroxycoumarin (aesculetin)
in multiple mouse organs. Toxicology Reports 2: 268-274.

22. Moffet RS (1964) Central nervous system depressants. VII pyridyl coumarins. J Med Chem 7: 446-449.

23. Kostova I, Raileva S, Genova P, Argirova R (2006) Structure-activity relationships of synthetic coumarins as HIV-1 inhibitors. Bioinorg Chem Appl 2006: 1-9.

24. Al-Haiza MA, Mosafa MS, El-Kady MY (2003) Synthesis and biological evaluation of some new coumarin derivatives. Molecules 8: 275-286.

25. Jung J, Kin J, Park OS (2001) A Convenient one-pot synthesis of 4-hydroxy coumarin, 4- hydroxy thiocoumarin and 4-hydroxy quinolin-2(1H)-one. Synth Commun 31: 1195-1200.

26. Vianna DK, Butols G, Meirelles G, Silva RV, Rocha A, et al. (2012) Evaluation of the Antioxidant Capacity of Synthesized Coumarins. Int J Mol Sci 13: 7260-7270.

27. Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC cells by L-dopa: implications for treatment of Parkinson's disease. J Chin Invest 95: 2458-2464.

28. De Leon-Rodriquez LM, Kovacz Z, Esquenada-Oliva AC, Miranda-Olvera AD (2006) Highly regioselective N-trans symmetrical dipeptide cyclodpeptide of cyclon. Tetrahedron Lett 47: 6937-6940.

29. Bellouard F, Chuburu F, Kervarec N, Toupet L, Triki S, et al. (1999) Cis-Diprotected cyclams and cyclens: a new route to symmetrically or asymmetrically 1,4-disubstituted tetraazamacrocycles and to asymmetrically tetrasubstituted derivatives. J Chem Soc Perkin Trans 23: 3499-3505.

30. Li C, Wong WT (2003) A Simple, Regioselective Synthesis of 1,4-Bis(tert-butoxycarbonylmethyl)-tetraazacyclododecane. J Org Chem 68: 2956-2959.

31. Yu M, Ryan TM, Ellis S, Bush Al, Triccas JA, et al. (2014) Neuroprotective peptide-macrocycle conjugates reveal complex structure-activity relationships in their interactions with amyloid β. Metallomics 6: 1931-1940.

32. Pallitto MM, Chanta J, Heinzelman P, Kiessling LL, Murphy RM (1999) Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry 38: 3570-3578.

33. Tjemebeng LO, Maslund J, Lindqvist F, Johansson J, Karlstrom AR, et al. (1996) Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271: 8545-8548.

34. Weber J, Keating GM (2009) Ropinirole prolonged release: in advanced Parkinson's disease. CNS Drugs 23: 81-90.

35. Djaldetti R, Melamed E (2001) New therapies for Parkinson's disease. J Neurol 248: 357-362.

36. Pilt R, Porreca F, Szabo LZ, Bilski E (1994) Glycopeptide enkephalin analogues produce analgesia in mice: Evidence for penetration of the blood-brain barrier. P Roc Natl Acad Sci USA 91: 7114-7118.

37. Bonina FP, Arenare L, Palagiano F, Saija A, Naia F, Trombetta DC (1999) Synthesis, stability and pharmacological evaluation of nipecotic acid prodrug. J Pharm Sci 88: 561-567.

38. Zhou T, Hider RC, Jenner P, Campbell B, Hobbs CJ, et al. (2013) Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate. Bioorg and Medicinal Chem Lett 23: 5279-5282.

39. Zhou T, Hider RC, Jenner P, Campbell B, Hobbs CJ, et al. (2010) Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease. European J Medicinal Chemistry 45: 4035-4042.